Oncology/endocrineEmpiric Antibiotics for Transarterial Embolization in Hepatocellular Carcinoma: Indicated?
Introduction
Hepatocellular carcinoma (HCC) continues to be one of the most rapidly rising cancers in the world with over 500,000 deaths attributed to this disease annually. From 1973 to 1998, there has been a 114% increase in the incidence of the disease in the United States alone, with 10 to 15,000 new cases diagnosed annually. It is estimated that by 2019, the yearly incidence will increase 2-fold [1]. Although resection, transplantation, and local ablative techniques (radio frequency ablation) remain the only potential curative modalities, only 30% of patients are considered suitable candidates. In addition, systemic chemotherapy has failed to demonstrate a survival benefit and has generally had a poor response rate [2].
Transarterial embolization (TAE) and transarterial chemoembolization (TACE) have become a common treatment option for patients with unresectable HCC for the purpose of palliation. This procedure has been widely performed for the past 20 years and the technique has evolved and has been well described in the literature. It has been used alone and in conjunction with radiofrequency ablation (RFA) with the theory that multimodality treatment will allow for increased tumor destruction and decreased local recurrence rates. One possible mechanism that may explain this is that tumor devascularization with transarterial embolization may decrease the heat sink effect by blood causing an increased zone of necrosis during RFA [3].
The rationale for using TAE to treat patients with HCC is as follows: the portal vein normally supplies 75% to 80% of the blood to hepatic parenchyma. In patients with HCC, however, the dominant blood supply is the hepatic artery. This anatomical reconfiguration by the tumor helps explain the efficacy of TAE. It also allows for tumor necrosis while preserving normal hepatic parenchyma.
Multiple meta-analyses have been performed demonstrating a survival benefit for patients receiving TAE versus symptomatic treatment [4]. In addition, a randomized control trial performed by Llovet and colleagues also showed a survival benefit in favor of the TAE treatment arm [5]. Due to these favorable results, it can be reasonable to expect that this modality will continue to be increasingly used.
Although techniques describing the procedure have been well documented, no standard protocols for pre- and post-procedure care have been devised. Specifically, the role of antibiotic prophylaxis against infection has not been evaluated. Generally, the use of antibiotics has been left to the discretion of the proceduralist, with the use hypothesized to reduce TAE associated liver abscess, but no supporting data exists for this practice. The objective of our study was to evaluate and examine the use of antibiotics in HCC patients undergoing TAE.
Section snippets
Methods
An institutional review board approved retrospective review of a prospectively created database of 1109 hepato-pancreatico-biliary patients from 1999 to 2007 was performed. All patients who underwent TAE, TACE, or Yttrium-90 were identified. Only patients who had histological or serological evidence of HCC were included in the study. All other lesions, including metastatic liver tumors, neuroendocrine, and other histological malignancies were excluded. We examined numerous endpoints including
Results
Two hundred and one patients were identified in the database who had hepatocellular cancer; 59 of those patients who underwent transarterial embolization were selected and reviewed. There were 46 men and 13 women (Table 1). The median length of stay was 1 d (0–5) depending on whether RFA was performed during the same hospitalization period. The median size of the largest lesion treated was 4 cm (2–11). The average number of lesions treated was 1 (1–4). The median AFP score was 18 (1.3–12,000).
Discussion
The findings of our study demonstrate that the routine use of antibiotics for post-procedure care in patients undergoing TAE, TACE, or Yttrium-90 as a treatment of HCC is unwarranted. No patient in our review developed infectious complications, including cholangitis, generalized sepsis, liver abscess, or pneumonia.
Historically, much emphasis has been places on antibiotic therapy before and after surgical procedures. However, a thorough search in the literature demonstrates a paucity of articles
References (10)
Chemoembolization and bland embolization: A critical appraisal
Clin Liver Dis
(2005)- et al.
Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: Treatment response based on tumor size and morphology
J Vasc Interv Radiol
(2002) - et al.
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Hepatology
(2003) - et al.
Transarterial embolization for hepatocellular carcinomaAntibiotic prophylaxis and clinical meaning of postembolization fever
J Hepatol
(1995) - et al.
Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies
J Vasc Interv Radiol
(2006)